← Eichor
Study identifier: NCT07668037 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy

Condition: Non-Small Cell Carcinoma of Lung · Immunotherapy · Advanced Non-Small Cell Lung Cancer  ·  Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

PhaseN/A
Planned participants600
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is a retrospective, multicenter, observational cohort study in patients with advanced or locally advanced non-small cell lung cancer (NSCLC). The aim of this study was to establish a long-term survival (LTS) versus short-term survival (STS) real-world cohort, to systematically characterize the multi-omics landscapes, and to develop and validate an artificial intelligence (AI) pathological prediction model based on routine H\&E-stained images for predicting immune microenvironment features and long-term survival outcomes following immunotherapy.

This description comes directly from the study's public registry record.

Talk to the study team

Jie Wang, MD,PhD  ·  8610-87788029  ·  zlhuxi@163.com

Jie Zhao, MD  ·  17801204737  ·  zhaojie_12@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Cancer Hospital Chinese Academy of Medical SciencesBeijing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07668037